JP2016523956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523956A5 JP2016523956A5 JP2016524933A JP2016524933A JP2016523956A5 JP 2016523956 A5 JP2016523956 A5 JP 2016523956A5 JP 2016524933 A JP2016524933 A JP 2016524933A JP 2016524933 A JP2016524933 A JP 2016524933A JP 2016523956 A5 JP2016523956 A5 JP 2016523956A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- vegf antagonist
- medicament according
- medicament
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 238000000315 cryotherapy Methods 0.000 claims 4
- 230000002207 retinal effect Effects 0.000 claims 4
- 229960003876 ranibizumab Drugs 0.000 claims 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845073P | 2013-07-11 | 2013-07-11 | |
| US61/845,073 | 2013-07-11 | ||
| PCT/IB2014/063003 WO2015004626A2 (en) | 2013-07-11 | 2014-07-10 | Use of a vegf antagonist in treating retinopathy of prematurity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016523956A JP2016523956A (ja) | 2016-08-12 |
| JP2016523956A5 true JP2016523956A5 (OSRAM) | 2017-08-17 |
Family
ID=51211284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524933A Pending JP2016523956A (ja) | 2013-07-11 | 2014-07-10 | 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20160159893A1 (OSRAM) |
| EP (1) | EP3019527A2 (OSRAM) |
| JP (1) | JP2016523956A (OSRAM) |
| KR (1) | KR20160030504A (OSRAM) |
| CN (1) | CN105377890A (OSRAM) |
| AR (1) | AR096893A1 (OSRAM) |
| AU (3) | AU2014288847A1 (OSRAM) |
| BR (1) | BR112016000282A2 (OSRAM) |
| CA (1) | CA2917813A1 (OSRAM) |
| HK (1) | HK1221231A1 (OSRAM) |
| MX (1) | MX2016000385A (OSRAM) |
| RU (1) | RU2676303C2 (OSRAM) |
| TW (1) | TW201536317A (OSRAM) |
| WO (1) | WO2015004626A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint Pharmaceuticals, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| CN105412094A (zh) | 2009-07-06 | 2016-03-23 | 爱尔皮奥治疗有限公司 | 用于防止癌细胞转移的化合物、组合物和方法 |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| ES2981607T3 (es) | 2015-09-23 | 2024-10-09 | Eyepoint Pharmaceuticals Inc | Activadores de Tie-2 para uso en el tratamiento de la presión intraocular |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| ES2903397T3 (es) | 2015-12-30 | 2022-04-01 | Marshall Univ Research Corporation | Composiciones y métodos para tratar la retinopatía |
| AU2017299581B2 (en) | 2016-07-20 | 2024-05-23 | EyePoint Pharmaceuticals, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-β) |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| AU2020264969B2 (en) | 2019-04-29 | 2025-06-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040265315A1 (en) * | 2002-09-05 | 2004-12-30 | Christine Dingivan | Methods of preventing or treating T cell malignancies by administering CD2 antagonists |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| EP2281885A1 (en) * | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| JP5838021B2 (ja) * | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| WO2007038453A2 (en) * | 2005-09-26 | 2007-04-05 | Advanced Ocular Systems Limited | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| KR20160040739A (ko) * | 2007-11-07 | 2016-04-14 | 안트로제네시스 코포레이션 | 조산 합병증의 치료에 있어서의 제대혈의 용도 |
| WO2010045506A2 (en) * | 2008-10-16 | 2010-04-22 | Kathleen Cogan Farinas | Sustained drug delivery system |
| CN102272148A (zh) | 2008-11-03 | 2011-12-07 | 分子组合公司 | 抑制vegf-a受体相互作用的结合蛋白 |
| EP3028707A1 (en) * | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
| US20140249191A1 (en) * | 2011-10-20 | 2014-09-04 | Avienne Pharmaceuticals Gmbh | Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases |
| MX363822B (es) * | 2012-08-21 | 2019-04-04 | Opko Pharmaceuticals Llc | Formulaciones de liposomas. |
-
2014
- 2014-07-10 RU RU2016104398A patent/RU2676303C2/ru not_active IP Right Cessation
- 2014-07-10 JP JP2016524933A patent/JP2016523956A/ja active Pending
- 2014-07-10 TW TW103123847A patent/TW201536317A/zh unknown
- 2014-07-10 KR KR1020167000259A patent/KR20160030504A/ko not_active Ceased
- 2014-07-10 CN CN201480039605.XA patent/CN105377890A/zh active Pending
- 2014-07-10 MX MX2016000385A patent/MX2016000385A/es unknown
- 2014-07-10 AU AU2014288847A patent/AU2014288847A1/en not_active Abandoned
- 2014-07-10 US US14/903,435 patent/US20160159893A1/en not_active Abandoned
- 2014-07-10 BR BR112016000282A patent/BR112016000282A2/pt not_active IP Right Cessation
- 2014-07-10 HK HK16109250.8A patent/HK1221231A1/zh unknown
- 2014-07-10 EP EP14741408.0A patent/EP3019527A2/en not_active Withdrawn
- 2014-07-10 CA CA2917813A patent/CA2917813A1/en not_active Abandoned
- 2014-07-10 WO PCT/IB2014/063003 patent/WO2015004626A2/en not_active Ceased
- 2014-07-11 AR ARP140102578A patent/AR096893A1/es unknown
-
2017
- 2017-06-26 AU AU2017204326A patent/AU2017204326A1/en not_active Abandoned
-
2019
- 2019-07-16 AU AU2019206000A patent/AU2019206000A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523956A5 (OSRAM) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| MX2020005166A (es) | Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos. | |
| JP2016518387A5 (OSRAM) | ||
| NZ725006A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| WO2015103438A3 (en) | Oncolytic virus adjunct therapy with agents that increase virus infectivity | |
| CL2019000245A1 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
| RU2016104398A (ru) | Использование антагониста vegf для лечения ретролентальной фиброплазии | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| JP2016530280A5 (OSRAM) | ||
| MX2018003028A (es) | Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc). | |
| CO2019000941A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| WO2017042633A3 (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| EP4289430A3 (en) | Thrombolytic agent and bevacizumab for treatment of cerebral ischemia | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| Sweet et al. | Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment | |
| HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. |